Doctor Details

Dr. Sumant Gupta
  • Name
    Dr. Sumant Gupta
  • Address
    Sarvodaya Hospital Research Centre Sector 8, Sarvodaya Medicentre
  • Designation
    Senior Consultant - Medical Oncology & BMT HOD - Sarvodaya Cancer Institute
  • Department

Dr. Sumant Gupta

Dr Sumant Gupta has been trained from prestigious Cancer Institute (WIA) Adyar, Chennai & All India Institute of Medical Sciences (AIIMS).  His Special interests include Haematological Malignancies & Bone Marrow transplants. He was instrumental in performing the first Bone Marrow Transplant in Faridabad. He was the winner of the TYSA Young Scholar Award (Medical Oncologist) for the Best DM - Oncology fellow (2015). He has more than 10 National & International papers in his credit. He is currently the executive committee member of the Indian Society of Oncology & Breast Cancer Foundation-India & Founder Executive Secretary of the National Cancer Society.


  • Adult Medical Oncology and Haemato-oncology
  • Paediatric Haemato-Oncology
  • Bone Marrow Transplantation


  • DM (Medical Oncology) from Cancer Institute (WIA) Adyar, Chennai
  • MD (Internal Medicine) from Chaudhary Charan Singh University, Meerut (UP)
  • MBBS from SSMC, Tumkur, Rajiv Gandhi University of Health Sciences Karnataka, India


  • Associate Consultant Medical Oncology at Batra Hospital, New Delhi
  • Senior Registrar at Department of Medical Oncology at All India Institute of Medical Sciences, New Delhi
  • DM (Medical Oncology and Paediatric Haemato-oncology) at Cancer Institute (WIA) Chennai


  • TYSA Young Scholar Award for the Best DM – Medical Oncology, 2015
  • Winner of TYACON Quiz at the Annual conference of Teen and young oncology 2013 at Delhi.

Other Information

Research and Publications :

  • Molecular Biology of Lung Cancer—A Review- Indian Journal of Surgical Oncology, Vol.4 No 2, 2013
  • Neutrophil response kinetics after G-CSF and Pef G-CSF usage post chemotherapy, Journal of Clinical Oncology Vol.26 No. 15S abst 20708, 2008
  • Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal hR3 (nimotuzumab) with chemotherapy- A study of toxicity profile and tolerance, journel of clinical Oncology vol.25.No 18S, abstract 14151, 2007
  • LYMPHOBLASTIC LEUKEMIA:A single centre experience with BFM-95 PROTOCOL with manuscript number ijmpo_227-14 is acceptable for publication in the journel